News und Analysen
Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?
A head-to-head competition for market share in the renal cell carcinoma (RCC) market appears to be about to intensify. In one corner is Bristol-Myers Squibb (NYSE: BMY). With a market cap of over....
3 Dividend Healthcare Stocks
One great reason to consider buying healthcare stocks is that demand for their products tends to remain stable in good times and bad. After all, no one gets to choose when they get sick. That....
3 Dividend Healthcare Stocks
One great reason to consider buying healthcare stocks is that demand for their products tends to remain stable in good times and bad. After all, no one gets to choose when they get sick. That....
3 Dividend Healthcare Stocks
One great reason to consider buying healthcare stocks is that demand for their products tends to remain stable in good times and bad. After all, no one gets to choose when they get sick. That....
Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings Jumped Today
The stock market was once again mixed on Thursday, with the Dow Jones Industrials gaining ground to set a record high for the third session in a row even as other major benchmarks lagged behind.....
Why Opko Health, Avis Budget Group, and Adomani Slumped Today
Thursday was another relatively quiet day for the stock market, and major benchmarks finished on either side of the unchanged mark by the end of the trading session. The Dow Jones Industrials hit....
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Take your seats, investors: The battle in first-line advanced renal cell carcinoma, the most common type of kidney cancer, is about to begin.In one corner, weighing in at a market cap of $8....
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Take your seats, investors: The battle in first-line advanced renal cell carcinoma, the most common type of kidney cancer, is about to begin.In one corner, weighing in at a market cap of $8....
Here's Why Halozyme Therapeutics, Inc. Is Soaring Today
Shares of Halozyme Therapeutics (NASDAQ: HALO), a small-cap biotech focused on creating products that help other drugs work more effectively, rose by 16% as of 10:45 a.m. EDT on Thursday.....
How Safe Is Abbott Labs' Dividend?
Abbott Laboratories (NYSE: ABT) has a long history of serving the healthcare community with its products. For much of its history, Abbott was a true healthcare conglomerate, producing both....
Here's Why the Best Is Yet to Come for Opko Health Inc.
There's not a whole lot that looks good for Opko Health Inc. (NASDAQ: OPK) right now. The stock has dropped more than 30% so far in 2017. Several large institutional investors have reduced their....
Here's Why the Best Is Yet to Come for Opko Health Inc.
There's not a whole lot that looks good for Opko Health Inc. (NASDAQ: OPK) right now. The stock has dropped more than 30% so far in 2017. Several large institutional investors have reduced their....
Investors' Biggest Worry About GW Pharmaceuticals Could Be the Biotech's Ace in the Hole
GW Pharmaceuticals' (NASDAQ: GWPH) stock soared more than 60% last year. So far in 2017, though, shares of the cannabinoid-focused biotech are down rather than up. One possible reason behind GW....
3 Biotech Stocks That Have Already Quadrupled in 2017
It's been a good year for biotech stocks, the iShares Nasdaq Biotechnology index has risen about 26% this year but a handful of companies make the industry tracking index's success seem trivial.....
3 Biotech Stocks That Have Already Quadrupled in 2017
It's been a good year for biotech stocks, the iShares Nasdaq Biotechnology index has risen about 26% this year but a handful of companies make the industry tracking index's success seem trivial.....
Why Equifax Inc Stock Dropped 12% Today
Shares of consumer credit bureau Equifax Inc. (NYSE: EFX) are down by about 12% as of 3:10 p.m. EDT as the company deals with fallout from a data breach that exposed the personal information --....
Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals)
Gilead Sciences' (NASDAQ: GILD) share repurchases last year could only be classified as horrible: The company bought back shares between $83.33 and $100 per share as the stock dropped....
Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals)
Gilead Sciences' (NASDAQ: GILD) share repurchases last year could only be classified as horrible: The company bought back shares between $83.33 and $100 per share as the stock dropped....
Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals)
Gilead Sciences' (NASDAQ: GILD) share repurchases last year could only be classified as horrible: The company bought back shares between $83.33 and $100 per share as the stock dropped....
ALPHA MOS : RESULTATS SEMESTRIELS 2017
Au cours de sa réunion du 11 septembre 2017, le Conseil d'administration d'Alpha MOS (Euronext Paris - Compartiment C - Code ISIN : FR0000062804-ALM) a arrêté les comptes semestriels 2017,....
ALPHA MOS : MISE A DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2017
Alpha MOS (Euronext Paris - Compartiment C - Code ISIN : FR0000062804-ALM) annonce, ce jour, avoir mis à la disposition du public et déposé auprès de l'Autorité des marchés financiers (AMF)....
5 Compelling Reasons Why AbbVie's Dividend Will Keep on Growing
What's the best dividend stock in all of big pharma? I would argue that the hands-down winner is AbbVie (NYSE: ABBV). The big biotech has the total package for dividend-seeking investors: a high....
5 Compelling Reasons Why AbbVie's Dividend Will Keep on Growing
What's the best dividend stock in all of big pharma? I would argue that the hands-down winner is AbbVie (NYSE: ABBV). The big biotech has the total package for dividend-seeking investors: a high....
5 Compelling Reasons Why AbbVie's Dividend Will Keep on Growing
What's the best dividend stock in all of big pharma? I would argue that the hands-down winner is AbbVie (NYSE: ABBV). The big biotech has the total package for dividend-seeking investors: a high....
Is the Sell-Off of Intercept Pharmaceuticals Stock Overblown?
Last year, a letter written by Chinese scholar Zeng Gong in 1080 sold for more than $30 million. It became the world's most expensive letter. However, a letter issued by Intercept Pharmaceuticals....